Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
View Patent ↗Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.
1. A method of augmenting autologous fat transfer to a subject, comprising:
removing a first portion of adipose tissue that comprises a cell population comprising adipose-derived stem cells from said subject;
introducing the removed adipose tissue into a self-contained cell processing unit configured to maintain a closed pathway;
isolating said cell population that comprises adipose-derived stem cells from mature adipocytes and connective tissue present in the removed adipose tissue so as to obtain a substantially isolated cell population comprising disaggregated adipose-derived stem cells, while maintaining a closed pathway;
concentrating said substantially isolated cell population comprising disaggregated adipose-derived stem cells so as to obtain a concentrated cell population that comprises disaggregated adipose-derived stem cells, while maintaining a closed pathway;
mixing said concentrated cell population comprising adipose-derived stem cells with a second portion of unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments obtained from said subject, so as to obtain an adipose tissue composition comprising a mixture of said concentrated cell population comprising disaggregated adipose-derived stem cells and said unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments tissue; and
reintroducing said adipose tissue composition into said subject.
2. The method of claim 1 , further comprising providing said mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells to a breast of the subject.
3. The method of claim 1 , further comprising providing said mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells to a soft-tissue region of the subject.
4. The method of claim 1 , further comprising providing said mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells to a urethral region of the subject.
5. The method of claim 1 , wherein the concentrated cell population that comprises disaggregated adipose-derived stem cells further comprises progenitor cells.
6. The method of claim 1 , multiple doses of the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises disaggregated adipose-derived stem cells is provided to said subject.
7. The method of claim 1 , further comprising providing an additive to the concentrated cell population that comprises disaggregated adipose-derived stem cells.
8. The method of claim 1 , further comprising providing an additive to the mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells.
9. The method of claim 1 , further comprising providing one or more angiogenic factors to the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells.
10. The method of claim 1 , further comprising providing the one or more arteriogenic factors to the mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells.
11. The method of claim 1 , further comprising providing one or more immunosuppressive drugs to the mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells.
12. The method of claim 1 , further comprising culturing said concentrated cell population that comprises disaggregated adipose-derived stem cells prior to mixing said concentrated cell population that comprises disaggregated adipose-derived stem cells with said second portion of unprocessed adipose tissue comprising intact, non disaggregated tissue fragments from said subject.
13. The method of claim 12 , wherein said culturing step comprises exposing said concentrated cell population that comprises disaggregated adipose-derived stem cells to culture conditions that promote differentiation towards an endothelial phenotype.
14. The method of claim 12 , wherein said culturing step is performed on a scaffold.
15. The method of claim 14 , wherein said scaffold is resorbable in vivo.
16. The method of claim 1 , wherein the mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells promotes neovascularization.
17. The method of claim 16 , wherein the neovascularization remains stable after the administered adipose-tissue composition is no longer present.
18. The method of claim 1 , wherein the mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells reduces necrosis.
19. The method of claim 1 , wherein the subject is human.
20. The method of claim 1 , wherein the concentrating step is done in a centrifuge.
21. The method of claim 1 , wherein the self-contained cell processing unit comprises a centrifuge disposed therein.
22. The method of claim 1 , wherein said mixture of the unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments and the concentrated cell population that comprises disaggregated adipose-derived stem cells is provided to said subject while maintaining the closed pathway.
23. The method of claim 1 , wherein said mixing step is performed while maintaining the closed pathway.